1 |
Qiu X, Xu H, Wang K, Gao F, Xu X, He H. P-21 Activated Kinases in Liver Disorders. Cancers (Basel) 2023;15. [PMID: 36672500 DOI: 10.3390/cancers15020551] [Reference Citation Analysis]
|
2 |
Jiang L, Li L, Liu Y, Lu L, Zhan M, Yuan S, Liu Y. Drug resistance mechanism of kinase inhibitors in the treatment of hepatocellular carcinoma. Front Pharmacol 2023;14:1097277. [PMID: 36891274 DOI: 10.3389/fphar.2023.1097277] [Reference Citation Analysis]
|
3 |
Zhou X, Ao X, Jia Z, Li Y, Kuang S, Du C, Zhang J, Wang J, Liu Y. Non-coding RNA in cancer drug resistance: Underlying mechanisms and clinical applications. Front Oncol 2022;12:951864. [PMID: 36059609 DOI: 10.3389/fonc.2022.951864] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
|
4 |
Hu H, Zhang T, Wu Y, Deng M, Deng H, Yang X. Cross-regulation between microRNAs and key proteins of signaling pathways in hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2022;16:753-65. [PMID: 35833844 DOI: 10.1080/17474124.2022.2101994] [Reference Citation Analysis]
|
5 |
Lou T, Zhang L, Jin Z, Miao C, Wang J, Ke K. miR-455-5p enhances 5-fluorouracil sensitivity in colorectal cancer cells by targeting PIK3R1 and DEPDC1. Open Medicine 2022;17:847-56. [DOI: 10.1515/med-2022-0474] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
6 |
Yang X, Cao D, Ma W, Gao S, Wen G, Zhong J. Wnt signaling in triple-negative breast cancers: Its roles in molecular subtyping and cancer cell stemness and its crosstalk with non-coding RNAs. Life Sciences 2022. [DOI: 10.1016/j.lfs.2022.120565] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
7 |
Huang PS, Liao CJ, Huang YH, Yeh CT, Chen CY, Tang HC, Chang CC, Lin KH. Functional and Clinical Significance of Dysregulated microRNAs in Liver Cancer. Cancers (Basel) 2021;13:5361. [PMID: 34771525 DOI: 10.3390/cancers13215361] [Reference Citation Analysis]
|